Optipharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Optipharm develops and supplies products and services across animal health, including veterinary disease diagnostics, animal medicines, and bacteriophage-based treatments, naturally occurring viruses that target and destroy harmful bacteria without affecting animal cells or beneficial microbes.
Its customers include livestock-related industries and research users who need diagnostic services and tested animal medicines. Listed on KOSDAQ, Korea's tech and small-cap board, the company's animal medicines division is its largest revenue contributor, followed by diagnostics and bacteriophage products.
Summary is AI-generated and may contain errors · figures from DART filings
Optipharm also produces genetically modified miniature pigs, sourced originally from the Sinclair Research Center in the US, for use in xenotransplantation research, applying gene-editing technologies to improve compatibility with human biology.
Optipharm in five facts
What does Optipharm do?
Optipharm develops and supplies products and services across animal health, including veterinary disease diagnostics, animal medicines, and bacteriophage-based treatments, naturally occurring viruses that target and destroy harmful bacteria without affecting animal cells or beneficial microbes.
Where is Optipharm listed and in which sector?
Optipharm (Korean name: 옵티팜) trades under KRX code 153710 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Optipharm?
Its market capitalisation was US$48.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Optipharm's latest annual revenue and operating profit?
For fiscal year 2025, Optipharm reported revenue of US$16.9M, an operating loss of US$1.8M and a net loss of US$1.9M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 13.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.